G D Ross|M J Polley - JoVE Visualize

Showing results (41-50 of 81) with videos related to

Pageof 9

Sort By:

Clinical and Experimental Immunology|February 5, 1999

Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I moleculesV Vĕtvicka, M Hanikýrová, J Vĕtvicková, et al.

Proceedings of the National Academy of Sciences of the United States of America|March 1, 1981

Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibodyJ D Lambris, N J Dobson, G D Ross

Clinical and Experimental Immunology|December 9, 1998

A mixed population of immature and mature leucocytes in umbilical cord blood results in a reduced expression and function of CR3 (CD11b/CD18)R K Reddy, Y Xia, M Hanikýrová, et al.

European Journal of Cell Biology|February 1, 1991

Phorbol ester induces transient focal concentrations of functional, newly expressed CR3 in neutrophils at sites of specific granule exocytosisK B Pryzwansky, T Wyatt, W Reed, et al.

Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1993

Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3V Vĕtvicka, W Reed, M L Hoover, et al.

Transplantation|August 1, 1979

Action of complement in the lysis of mouse sarcoma cells sensitized with H-2 alloantibodyA B Reske-Kunz, M P Scheid, J Abbott, et al.

The Journal of Clinical Investigation|October 1, 1992

Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140)M S Mulligan, M J Polley, R J Bayer, et al.

Proceedings of the National Academy of Sciences of the United States of America|July 15, 1991

CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis xM J Polley, M L Phillips, E Wayner, et al.

Immunopharmacology|July 17, 1999

Therapeutic intervention with complement and beta-glucan in cancerG D Ross, V Vetvicka, J Yan, et al.

Journal of Immunology (Baltimore, Md. : 1950)|July 15, 1997

Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18)V Vetvicka, B P Thornton, T J Wieman, et al.

Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:

Pageof 9

Clinical and Experimental Immunology|February 5, 1999

Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I moleculesV Vĕtvicka, M Hanikýrová, J Vĕtvicková, et al.

Proceedings of the National Academy of Sciences of the United States of America|March 1, 1981

Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibodyJ D Lambris, N J Dobson, G D Ross

Clinical and Experimental Immunology|December 9, 1998

A mixed population of immature and mature leucocytes in umbilical cord blood results in a reduced expression and function of CR3 (CD11b/CD18)R K Reddy, Y Xia, M Hanikýrová, et al.

European Journal of Cell Biology|February 1, 1991

Phorbol ester induces transient focal concentrations of functional, newly expressed CR3 in neutrophils at sites of specific granule exocytosisK B Pryzwansky, T Wyatt, W Reed, et al.

Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1993

Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3V Vĕtvicka, W Reed, M L Hoover, et al.

Transplantation|August 1, 1979

Action of complement in the lysis of mouse sarcoma cells sensitized with H-2 alloantibodyA B Reske-Kunz, M P Scheid, J Abbott, et al.

The Journal of Clinical Investigation|October 1, 1992

Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140)M S Mulligan, M J Polley, R J Bayer, et al.

Proceedings of the National Academy of Sciences of the United States of America|July 15, 1991

CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis xM J Polley, M L Phillips, E Wayner, et al.

Immunopharmacology|July 17, 1999

Therapeutic intervention with complement and beta-glucan in cancerG D Ross, V Vetvicka, J Yan, et al.

Journal of Immunology (Baltimore, Md. : 1950)|July 15, 1997

Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18)V Vetvicka, B P Thornton, T J Wieman, et al.

Pageof 9